Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Evaluating hybrid controls methodology in early-phase oncology trials: a simulation study based on the MORPHEUS-UC trial

Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Adaptive Hybrid Control Design for Comparative Clinical Trials with Historical Control Data

Case weighted power priors for hybrid control analyses with time-to-event data

Incorporating Historical Information to Improve Phase I Clinical Trials

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling

A Bayesian Hybrid Design with Borrowing from Historical Study

Optimal Bayesian Hierarchical Model to Accelerate the Development of Tissue-Agnostic Drugs and Basket Trials.

Hybrid Design Evaluating New Biomarkers when There is an Existing Screening Test

MIDAS: a Practical Bayesian Design for Platform Trials with Molecularly Targeted Agents

A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications

A multistate model for early decision making in oncology

Hierarchical Bayesian Clustering Design of Multiple Biomarker Subgroups (HCOMBS)

Augmenting treatment arms with external data through propensity-score weighted power-priors: an application in expanded access

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150